CA3117102A1 - Type i interferon signatures and methods of use - Google Patents
Type i interferon signatures and methods of use Download PDFInfo
- Publication number
- CA3117102A1 CA3117102A1 CA3117102A CA3117102A CA3117102A1 CA 3117102 A1 CA3117102 A1 CA 3117102A1 CA 3117102 A CA3117102 A CA 3117102A CA 3117102 A CA3117102 A CA 3117102A CA 3117102 A1 CA3117102 A1 CA 3117102A1
- Authority
- CA
- Canada
- Prior art keywords
- ifn
- subject
- genes
- biological sample
- poise
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 126
- 102000002227 Interferon Type I Human genes 0.000 title claims abstract description 50
- 108010014726 Interferon Type I Proteins 0.000 title claims abstract description 50
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 134
- 201000010099 disease Diseases 0.000 claims abstract description 129
- 239000003112 inhibitor Substances 0.000 claims abstract description 120
- 230000001404 mediated effect Effects 0.000 claims abstract description 94
- 238000011282 treatment Methods 0.000 claims abstract description 80
- 230000014509 gene expression Effects 0.000 claims description 215
- 239000012472 biological sample Substances 0.000 claims description 140
- 102100039922 E3 ISG15-protein ligase HERC5 Human genes 0.000 claims description 111
- 101001035145 Homo sapiens E3 ISG15-protein ligase HERC5 Proteins 0.000 claims description 111
- 101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 claims description 111
- 101000864662 Homo sapiens Probable ATP-dependent RNA helicase DHX58 Proteins 0.000 claims description 111
- 101001032342 Homo sapiens Interferon regulatory factor 7 Proteins 0.000 claims description 110
- 101001067396 Homo sapiens Phospholipid scramblase 1 Proteins 0.000 claims description 110
- 101000735459 Homo sapiens Protein mono-ADP-ribosyltransferase PARP9 Proteins 0.000 claims description 110
- 101000822540 Homo sapiens Sterile alpha motif domain-containing protein 9-like Proteins 0.000 claims description 110
- 102100038070 Interferon regulatory factor 7 Human genes 0.000 claims description 110
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 claims description 110
- 102100034627 Phospholipid scramblase 1 Human genes 0.000 claims description 110
- 102100034930 Protein mono-ADP-ribosyltransferase PARP9 Human genes 0.000 claims description 110
- 102100022459 Sterile alpha motif domain-containing protein 9-like Human genes 0.000 claims description 109
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 108
- 239000000523 sample Substances 0.000 claims description 43
- 238000003753 real-time PCR Methods 0.000 claims description 33
- 239000008280 blood Substances 0.000 claims description 30
- 210000004369 blood Anatomy 0.000 claims description 29
- 230000003042 antagnostic effect Effects 0.000 claims description 26
- 206010025135 lupus erythematosus Diseases 0.000 claims description 26
- 101001082070 Homo sapiens Interferon alpha-inducible protein 6 Proteins 0.000 claims description 24
- 102100027354 Interferon alpha-inducible protein 6 Human genes 0.000 claims description 24
- 101000840293 Homo sapiens Interferon-induced protein 44 Proteins 0.000 claims description 20
- 101000959664 Homo sapiens Interferon-induced protein 44-like Proteins 0.000 claims description 20
- 102100029607 Interferon-induced protein 44 Human genes 0.000 claims description 20
- 102100039953 Interferon-induced protein 44-like Human genes 0.000 claims description 20
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 claims description 14
- 208000027066 STING-associated vasculopathy with onset in infancy Diseases 0.000 claims description 14
- 206010073960 CANDLE syndrome Diseases 0.000 claims description 13
- 208000017502 proteosome-associated autoinflammatory syndrome Diseases 0.000 claims description 13
- 208000033237 Aicardi-Goutières syndrome Diseases 0.000 claims description 9
- 210000003169 central nervous system Anatomy 0.000 claims description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 9
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 8
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 7
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 7
- 201000001981 dermatomyositis Diseases 0.000 claims description 7
- 108020004999 messenger RNA Proteins 0.000 claims description 7
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims description 7
- 208000005987 polymyositis Diseases 0.000 claims description 7
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 6
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 6
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 claims description 6
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 6
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims description 6
- 206010052779 Transplant rejections Diseases 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 230000003993 interaction Effects 0.000 claims description 5
- 238000002493 microarray Methods 0.000 claims description 5
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 101000641015 Homo sapiens Sterile alpha motif domain-containing protein 9 Proteins 0.000 claims 1
- 102100034291 Sterile alpha motif domain-containing protein 9 Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 91
- 238000001990 intravenous administration Methods 0.000 description 52
- 239000000902 placebo Substances 0.000 description 52
- 229940068196 placebo Drugs 0.000 description 52
- 230000004044 response Effects 0.000 description 44
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 27
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 24
- 108700039887 Essential Genes Proteins 0.000 description 24
- 239000003814 drug Substances 0.000 description 24
- 208000015181 infectious disease Diseases 0.000 description 22
- 238000007920 subcutaneous administration Methods 0.000 description 22
- 230000008859 change Effects 0.000 description 21
- 229940079593 drug Drugs 0.000 description 21
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 17
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 17
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 17
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 17
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 16
- 230000003285 pharmacodynamic effect Effects 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 238000012216 screening Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 13
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 13
- 108010047761 Interferon-alpha Proteins 0.000 description 13
- 102000006992 Interferon-alpha Human genes 0.000 description 13
- 108091033319 polynucleotide Proteins 0.000 description 13
- 102000040430 polynucleotide Human genes 0.000 description 13
- 239000002157 polynucleotide Substances 0.000 description 13
- 230000001629 suppression Effects 0.000 description 13
- 208000007514 Herpes zoster Diseases 0.000 description 11
- 102100030090 Probable ATP-dependent RNA helicase DHX58 Human genes 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 238000001802 infusion Methods 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 230000009266 disease activity Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 229940113082 thymine Drugs 0.000 description 9
- 229940035893 uracil Drugs 0.000 description 9
- 102000014150 Interferons Human genes 0.000 description 8
- 108010050904 Interferons Proteins 0.000 description 8
- 230000001363 autoimmune Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 229940079322 interferon Drugs 0.000 description 8
- -1 rRNA Proteins 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 230000002411 adverse Effects 0.000 description 7
- 208000037976 chronic inflammation Diseases 0.000 description 7
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 101150072531 10 gene Proteins 0.000 description 6
- 208000021386 Sjogren Syndrome Diseases 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000013068 control sample Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 5
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 5
- 238000003559 RNA-seq method Methods 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 229950010117 anifrolumab Drugs 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000007637 random forest analysis Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 208000005777 Lupus Nephritis Diseases 0.000 description 4
- 208000033212 Myringitis bullous Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 230000003460 anti-nuclear Effects 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 230000001174 ascending effect Effects 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000008482 dysregulation Effects 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 238000010801 machine learning Methods 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- 102100040685 14-3-3 protein zeta/delta Human genes 0.000 description 3
- AQQSXKSWTNWXKR-UHFFFAOYSA-N 2-(2-phenylphenanthro[9,10-d]imidazol-3-yl)acetic acid Chemical compound C1(=CC=CC=C1)C1=NC2=C(N1CC(=O)O)C1=CC=CC=C1C=1C=CC=CC=12 AQQSXKSWTNWXKR-UHFFFAOYSA-N 0.000 description 3
- TUOZJWZCVIRDKO-UHFFFAOYSA-N 6,7-dimethoxy-2-[4-(4-methylpiperazin-1-yl)phenyl]-n-(2-morpholin-4-ylethyl)quinazolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC(C=2C=CC(=CC=2)N2CCN(C)CC2)=NC=1NCCN1CCOCC1 TUOZJWZCVIRDKO-UHFFFAOYSA-N 0.000 description 3
- 102100026031 Beta-glucuronidase Human genes 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102100021429 DNA-directed RNA polymerase II subunit RPB1 Human genes 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101000964898 Homo sapiens 14-3-3 protein zeta/delta Proteins 0.000 description 3
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 description 3
- 101001106401 Homo sapiens DNA-directed RNA polymerase II subunit RPB1 Proteins 0.000 description 3
- 101000896557 Homo sapiens Eukaryotic translation initiation factor 3 subunit B Proteins 0.000 description 3
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 3
- 101001067833 Homo sapiens Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 description 3
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 description 3
- 101000662049 Homo sapiens Polyubiquitin-C Proteins 0.000 description 3
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 3
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 3
- 206010061217 Infestation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 description 3
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 3
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 3
- 102100037935 Polyubiquitin-C Human genes 0.000 description 3
- 101710189720 Porphobilinogen deaminase Proteins 0.000 description 3
- 102100034391 Porphobilinogen deaminase Human genes 0.000 description 3
- 101710170827 Porphobilinogen deaminase, chloroplastic Proteins 0.000 description 3
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 3
- 206010036600 Premature labour Diseases 0.000 description 3
- 101710100896 Probable porphobilinogen deaminase Proteins 0.000 description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 3
- 101710156592 Putative TATA-binding protein pB263R Proteins 0.000 description 3
- 239000013614 RNA sample Substances 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 102100040296 TATA-box-binding protein Human genes 0.000 description 3
- 101710145783 TATA-box-binding protein Proteins 0.000 description 3
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- HDRGJRSISASRAJ-WKPMUQCKSA-N bazlitoran Chemical compound CO[C@@H]1[C@H](O)[C@@H](COP(=O)(S)O[C@@H]2[C@@H](COP(=O)(S)O[C@H]3C[C@@H](O[C@@H]3COP(=O)(S)O[C@H]4C[C@@H](O[C@@H]4COP(=O)(S)O[C@H]5C[C@@H](O[C@@H]5COP(=O)(S)O[C@H]6C[C@@H](O[C@@H]6COP(=O)(S)O[C@H]7C[C@@H](O[C@@H]7COP(=O)(S)O[C@H]8C[C@@H](O[C@@H]8COP(=O)(S)O[C@H]9C[C@@H](O[C@@H]9COP(=O)(S)O[C@H]%10C[C@@H](O[C@@H]%10COP(=O)(S)O[C@@H]%11[C@@H](COP(=O)(S)O[C@@H]%12[C@@H](COP(=O)(S)O[C@H]%13C[C@@H](O[C@@H]%13COP(=O)(S)O[C@H]%14C[C@@H](O[C@@H]%14COP(=O)(S)O[C@H]%15C[C@@H](O[C@@H]%15COP(=O)(S)O[C@H]%16C[C@@H](O[C@@H]%16COP(=O)(S)O[C@H]%17C[C@@H](O[C@@H]%17COP(=O)(S)O[C@H]%18C[C@@H](O[C@@H]%18CO)N%19C=CC(=NC%19=O)N)N%20C=C(C)C(=O)NC%20=O)n%21cnc%22c(N)ncnc%21%22)N%23C=C(C)C(=O)NC%23=O)N%24C=CC(=NC%24=O)N)N%25C=C(C)C(=O)NC%25=O)O[C@H]([C@@H]%12OC)n%26cnc%27C(=O)NC(=Nc%26%27)N)O[C@H]([C@@H]%11OC)N%28C=CC(=O)NC%28=O)N%29C=C(C)C(=NC%29=O)N)n%30ccc%31C(=O)NC(=Nc%30%31)N)N%32C=C(C)C(=O)NC%32=O)N%33C=C(C)C(=O)NC%33=O)N%34C=CC(=NC%34=O)N)N%35C=C(C)C(=O)NC%35=O)N%36C=CC(=NC%36=O)N)N%37C=C(C)C(=O)NC%37=O)O[C@H]([C@@H]2OC)n%38cnc%39C(=O)NC(=Nc%38%39)N)O[C@H]1N%40C=CC(=O)NC%40=O HDRGJRSISASRAJ-WKPMUQCKSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000004547 gene signature Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 208000026440 premature labor Diseases 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000013074 reference sample Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- HEDPDFHTQKEORT-UHFFFAOYSA-N 2-(2-chloro-6-fluorophenyl)-5-[4-(morpholine-4-carbonyl)anilino]-1,3-oxazole-4-carboxamide Chemical compound NC(=O)C=1N=C(C=2C(=CC=CC=2F)Cl)OC=1NC(C=C1)=CC=C1C(=O)N1CCOCC1 HEDPDFHTQKEORT-UHFFFAOYSA-N 0.000 description 2
- 101150042997 21 gene Proteins 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- 102100028668 C-type lectin domain family 4 member C Human genes 0.000 description 2
- DADAEARVGOQWHV-OSYLJGHBSA-N CC1=CC(NC2=NC(N[C@H]3C[C@@H]4CC[C@H](C3)N4CCC#N)=C3C=CC=NC3=C2)=NN1 Chemical compound CC1=CC(NC2=NC(N[C@H]3C[C@@H]4CC[C@H](C3)N4CCC#N)=C3C=CC=NC3=C2)=NN1 DADAEARVGOQWHV-OSYLJGHBSA-N 0.000 description 2
- BUWBRTXGQRBBHG-MJBXVCDLSA-N FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C)F Chemical compound FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C)F BUWBRTXGQRBBHG-MJBXVCDLSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 206010018735 Groin pain Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000766907 Homo sapiens C-type lectin domain family 4 member C Proteins 0.000 description 2
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 description 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 2
- 101000984199 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 4 Proteins 0.000 description 2
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 2
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 102100025555 Leukocyte immunoglobulin-like receptor subfamily A member 4 Human genes 0.000 description 2
- 208000008771 Lymphadenopathy Diseases 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004012 Tofacitinib Substances 0.000 description 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 2
- 229940123371 Tyrosine kinase 2 inhibitor Drugs 0.000 description 2
- XDJGNPSZQSWJCV-UHFFFAOYSA-N [2-[6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl]-3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]-(5-piperidin-1-ylpyrazin-2-yl)methanone Chemical group CCC1=CC(O)=C(F)C=C1C1=CC=C(C(=NN2)C=3NC=4CCN(CC=4N=3)C(=O)C=3N=CC(=NC=3)N3CCCCC3)C2=C1 XDJGNPSZQSWJCV-UHFFFAOYSA-N 0.000 description 2
- IUEWXNHSKRWHDY-PHIMTYICSA-N abrocitinib Chemical compound C1[C@@H](NS(=O)(=O)CCC)C[C@H]1N(C)C1=NC=NC2=C1C=CN2 IUEWXNHSKRWHDY-PHIMTYICSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229940010849 brepocitinib Drugs 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
- 229960004171 hydroxychloroquine Drugs 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 229960001388 interferon-beta Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 208000018555 lymphatic system disease Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229950010316 rontalizumab Drugs 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 229960001350 tofacitinib Drugs 0.000 description 2
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- WYQFJHHDOKWSHR-MNOVXSKESA-N (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide Chemical compound CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2N1C(C=CN1)=C1N=C2 WYQFJHHDOKWSHR-MNOVXSKESA-N 0.000 description 1
- DNBCBAXDWNDRNO-FOSCPWQOSA-N (3aS,6aR)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxamide Chemical compound COC1=NSC(NC(=O)N2C[C@H]3CC(C[C@H]3C2)N(C)C=2C=3C=CNC=3N=CN=2)=N1 DNBCBAXDWNDRNO-FOSCPWQOSA-N 0.000 description 1
- BFENHEAPFWQJFL-BTJKTKAUSA-N (Z)-but-2-enedioic acid N-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound OC(=O)\C=C/C(O)=O.O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1 BFENHEAPFWQJFL-BTJKTKAUSA-N 0.000 description 1
- 102100027769 2'-5'-oligoadenylate synthase 1 Human genes 0.000 description 1
- 102100027621 2'-5'-oligoadenylate synthase 2 Human genes 0.000 description 1
- 102100035389 2'-5'-oligoadenylate synthase 3 Human genes 0.000 description 1
- KTBSXLIQKWEBRB-UHFFFAOYSA-N 2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CN=C(C(F)(F)F)C(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 KTBSXLIQKWEBRB-UHFFFAOYSA-N 0.000 description 1
- YMZPQKXPKZZSFV-CPWYAANMSA-N 2-[3-[(1r)-1-[(2s)-1-[(2s)-2-[(1r)-cyclohex-2-en-1-yl]-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carbonyl]oxy-3-(3,4-dimethoxyphenyl)propyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H]([C@H]2C=CCCC2)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 YMZPQKXPKZZSFV-CPWYAANMSA-N 0.000 description 1
- GTVAUHXUMYENSK-RWSKJCERSA-N 2-[3-[(1r)-3-(3,4-dimethoxyphenyl)-1-[(2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)pent-4-enoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC=C)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GTVAUHXUMYENSK-RWSKJCERSA-N 0.000 description 1
- NDUGGMXIZKDJRM-UHFFFAOYSA-N 3-[[2-(3,4,5-trimethoxyanilino)-7h-purin-6-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical group COC1=C(OC)C(OC)=CC(NC=2N=C3N=CNC3=C(NC3C(C4CC3C=C4)C(N)=O)N=2)=C1 NDUGGMXIZKDJRM-UHFFFAOYSA-N 0.000 description 1
- 101150017816 40 gene Proteins 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- BZZKEPGENYLQSC-FIBGUPNXSA-N 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound C1(CC1)C(=O)NC1=CC(=C(N=N1)C(=O)NC([2H])([2H])[2H])NC1=C(C(=CC=C1)C1=NN(C=N1)C)OC BZZKEPGENYLQSC-FIBGUPNXSA-N 0.000 description 1
- DVCPYUTZIIXGFE-UHFFFAOYSA-N 649nj54i9p Chemical compound ClC1=CC=CC(Cl)=C1C1=NC(C2=CC=CN=C2NC2=CN=CC=C22)=C2N1 DVCPYUTZIIXGFE-UHFFFAOYSA-N 0.000 description 1
- 241001523209 Antissa Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 229940124282 BMS-986165 Drugs 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- XPLZTJWZDBFWDE-OYOVHJISSA-N CN1C=C(C=N1)C1=CN2N=CC=C2C(=N1)C1=CN(N=C1)[C@@]1(CC#N)C[C@@H](C1)C#N Chemical compound CN1C=C(C=N1)C1=CN2N=CC=C2C(=N1)C1=CN(N=C1)[C@@]1(CC#N)C[C@@H](C1)C#N XPLZTJWZDBFWDE-OYOVHJISSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 102100029375 Crk-like protein Human genes 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102100039621 Epithelial-stromal interaction protein 1 Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 101001008907 Homo sapiens 2'-5'-oligoadenylate synthase 1 Proteins 0.000 description 1
- 101001008910 Homo sapiens 2'-5'-oligoadenylate synthase 2 Proteins 0.000 description 1
- 101000597332 Homo sapiens 2'-5'-oligoadenylate synthase 3 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000919315 Homo sapiens Crk-like protein Proteins 0.000 description 1
- 101000814134 Homo sapiens Epithelial-stromal interaction protein 1 Proteins 0.000 description 1
- 101001128393 Homo sapiens Interferon-induced GTP-binding protein Mx1 Proteins 0.000 description 1
- 101001082065 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 description 1
- 101001082060 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 3 Proteins 0.000 description 1
- 101001065568 Homo sapiens Lymphocyte antigen 6E Proteins 0.000 description 1
- 101000604998 Homo sapiens Lysosome-associated membrane glycoprotein 3 Proteins 0.000 description 1
- 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 description 1
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 1
- 101000657037 Homo sapiens Radical S-adenosyl methionine domain-containing protein 2 Proteins 0.000 description 1
- 101000635777 Homo sapiens Receptor-transporting protein 4 Proteins 0.000 description 1
- 101000828739 Homo sapiens SPATS2-like protein Proteins 0.000 description 1
- 101000825071 Homo sapiens Sclerostin domain-containing protein 1 Proteins 0.000 description 1
- 101000868472 Homo sapiens Sialoadhesin Proteins 0.000 description 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 101001057508 Homo sapiens Ubiquitin-like protein ISG15 Proteins 0.000 description 1
- 101000644847 Homo sapiens Ubl carboxyl-terminal hydrolase 18 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101710169201 Interferon alpha-inducible protein 6 Proteins 0.000 description 1
- 102100031802 Interferon-induced GTP-binding protein Mx1 Human genes 0.000 description 1
- 101710197212 Interferon-induced protein 44 Proteins 0.000 description 1
- 101710142533 Interferon-induced protein 44-like Proteins 0.000 description 1
- 102100027355 Interferon-induced protein with tetratricopeptide repeats 1 Human genes 0.000 description 1
- 102100027302 Interferon-induced protein with tetratricopeptide repeats 3 Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 206010065048 Latent tuberculosis Diseases 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- 102100032131 Lymphocyte antigen 6E Human genes 0.000 description 1
- 102100038213 Lysosome-associated membrane glycoprotein 3 Human genes 0.000 description 1
- 102100027252 Melanoma-associated antigen C2 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010058105 Neutrophilic dermatosis Diseases 0.000 description 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108010078627 Oncogene Protein v-crk Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 229940124281 PF-06826647 Drugs 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 101710149609 Phospholipid scramblase 1 Proteins 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102100033749 Radical S-adenosyl methionine domain-containing protein 2 Human genes 0.000 description 1
- 102100030854 Receptor-transporting protein 4 Human genes 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 102100023521 SPATS2-like protein Human genes 0.000 description 1
- 108010076622 SS-A antigen Proteins 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100032855 Sialoadhesin Human genes 0.000 description 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
- 102000000887 Transcription factor STAT Human genes 0.000 description 1
- 108050007918 Transcription factor STAT Proteins 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 102100027266 Ubiquitin-like protein ISG15 Human genes 0.000 description 1
- 102100020726 Ubl carboxyl-terminal hydrolase 18 Human genes 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- ZMJWRJKGPUDEOX-LMXUULCNSA-A alicaforsen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([S-])(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 ZMJWRJKGPUDEOX-LMXUULCNSA-A 0.000 description 1
- 229950011466 alicaforsen Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229950000971 baricitinib Drugs 0.000 description 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- DREIJXJRTLTGJC-ZLBJMMTISA-N chembl3137308 Chemical compound C([C@H]1C[C@@](O)(C2)C3)C2C[C@H]3[C@H]1NC1=C2C=CNC2=NC=C1C(=O)N DREIJXJRTLTGJC-ZLBJMMTISA-N 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 108091008147 housekeeping proteins Proteins 0.000 description 1
- 102000057897 human SOSTDC1 Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 108010045648 interferon omega 1 Proteins 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229950001890 itacitinib Drugs 0.000 description 1
- 229940126397 ivarmacitinib Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- JABGXPCRNXUENL-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1N=CNC2=NC=N[C]12 JABGXPCRNXUENL-UHFFFAOYSA-N 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229950008814 momelotinib Drugs 0.000 description 1
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- MPYACSQFXVMWNO-UHFFFAOYSA-N n-[5-[4-(3,3-dimethylazetidine-1-carbonyl)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1C(C)(C)CN1C(=O)C1=CC=C(C=2N3N=C(NC(=O)C4CC4)N=C3C=CC=2)C=C1 MPYACSQFXVMWNO-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 229940124624 oral corticosteroid Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229950005157 peficitinib Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940126457 povorcitinib Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000004911 serous fluid Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229950009133 solcitinib Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229950007205 talacotuzumab Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229950000088 upadacitinib Drugs 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000009528 vital sign measurement Methods 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2539/00—Reactions characterised by analysis of gene expression or genome comparison
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2545/00—Reactions characterised by their quantitative nature
- C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
- C12Q2545/114—Reactions characterised by their quantitative nature the purpose being quantitative analysis involving a quantitation step
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Primary Health Care (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862751019P | 2018-10-26 | 2018-10-26 | |
| US62/751,019 | 2018-10-26 | ||
| PCT/IB2019/059178 WO2020084591A1 (en) | 2018-10-26 | 2019-10-25 | Type i interferon signatures and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3117102A1 true CA3117102A1 (en) | 2020-04-30 |
Family
ID=70328348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3117102A Pending CA3117102A1 (en) | 2018-10-26 | 2019-10-25 | Type i interferon signatures and methods of use |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12009079B2 (enExample) |
| EP (1) | EP3873523A4 (enExample) |
| JP (2) | JP2022512796A (enExample) |
| KR (1) | KR20210084528A (enExample) |
| CN (1) | CN113692287A (enExample) |
| CA (1) | CA3117102A1 (enExample) |
| EA (1) | EA202191133A1 (enExample) |
| IL (1) | IL282479A (enExample) |
| MA (1) | MA54085A (enExample) |
| WO (1) | WO2020084591A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114836534A (zh) * | 2021-06-08 | 2022-08-02 | 中国医学科学院北京协和医院 | Samd9l基因突变作为i型干扰素病诊断的标志物及其应用 |
| CA3266513A1 (en) | 2022-09-14 | 2024-03-21 | Viatris Asia Pacific Pte. Ltd. | S1P1 RECEPTOR MODULATORS INTENDED FOR USE IN THE TREATMENT OF TYPE 1 IFN-MEDICATED DISEASES |
| WO2024100139A1 (en) * | 2022-11-09 | 2024-05-16 | Merck Patent Gmbh | Use of ifn-i activity as a biomarker for tlr inhibitor treatment |
| WO2024173764A1 (en) * | 2023-02-16 | 2024-08-22 | Alumis Inc. | Methods of treating hidradenitis suppurativa |
| EP4665349A1 (en) * | 2023-02-16 | 2025-12-24 | Alumis Inc. | Methods of treating dermatological disorders |
| WO2024201091A1 (en) * | 2023-03-27 | 2024-10-03 | Institut National de la Santé et de la Recherche Médicale | A gene signature for diagnosing stimulator of interferon genes (sting)-associated vasculopathy with onset in infancy (savi) |
| WO2024216160A1 (en) * | 2023-04-14 | 2024-10-17 | Arc Research Institute | Methods and compositions for using peli2 as a biomarker |
| CN117138038A (zh) * | 2023-09-21 | 2023-12-01 | 北京大学 | 一种预防、治疗或缓解椎体后纵韧带骨化症的药物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0613387A2 (pt) * | 2005-07-08 | 2011-01-11 | Biogen Idec Inc | anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone |
| RU2527068C2 (ru) | 2006-12-06 | 2014-08-27 | Медиммун, Ллк | Фармакодинамические маркеры, индуцированные интерфероном альфа |
| EP2068924A4 (en) * | 2007-05-03 | 2011-07-20 | Medimmune Llc | INTERFERON ALPHA INDUCED PHARMACODYNAMIC MARKERS |
| EP2419727A1 (en) * | 2009-04-14 | 2012-02-22 | Schering Corporation | Interferon-alfa sensitivity biomarkers |
| US20130261018A1 (en) * | 2010-10-20 | 2013-10-03 | University Of Tennessee Research Foundation | Interferon gene signature and methods of use thereof |
| CA2834203A1 (en) * | 2011-04-26 | 2012-11-01 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| RU2013157177A (ru) * | 2011-05-25 | 2015-06-27 | МЕДИММЬЮН, ЭлЭлСи | Способы лечения системной красной волчанки, склеродермии и миозита |
| WO2013101771A2 (en) * | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| KR102320059B1 (ko) * | 2012-06-13 | 2021-11-01 | 아스트라제네카 아베 | 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획 |
| US10689441B2 (en) * | 2013-12-06 | 2020-06-23 | Novimmune Sa | Anti—TLR4 antibodies and methods of use thereof |
| TWI713453B (zh) * | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
| US10689703B2 (en) * | 2015-04-27 | 2020-06-23 | National Jewish Health | Methods of identifying and treating subjects having acute respiratory distress syndrome |
| CN109963870B (zh) * | 2016-06-08 | 2023-07-28 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
| EP3947448A4 (en) * | 2019-04-04 | 2023-02-01 | Janssen Biotech, Inc. | PROCEDURE FOR ADMINISTRATION OF AN ANTI-IFN ALPHA/OMEGA ANTIBODY |
-
2019
- 2019-10-25 CN CN201980086249.XA patent/CN113692287A/zh active Pending
- 2019-10-25 MA MA054085A patent/MA54085A/fr unknown
- 2019-10-25 CA CA3117102A patent/CA3117102A1/en active Pending
- 2019-10-25 KR KR1020217015505A patent/KR20210084528A/ko not_active Withdrawn
- 2019-10-25 WO PCT/IB2019/059178 patent/WO2020084591A1/en not_active Ceased
- 2019-10-25 JP JP2021522350A patent/JP2022512796A/ja not_active Withdrawn
- 2019-10-25 EP EP19874869.1A patent/EP3873523A4/en not_active Withdrawn
- 2019-10-25 US US16/663,527 patent/US12009079B2/en active Active
- 2019-10-25 EA EA202191133A patent/EA202191133A1/ru unknown
-
2021
- 2021-04-20 IL IL282479A patent/IL282479A/en unknown
-
2024
- 2024-06-04 JP JP2024090820A patent/JP2024119889A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024119889A (ja) | 2024-09-03 |
| IL282479A (en) | 2021-06-30 |
| CN113692287A (zh) | 2021-11-23 |
| EP3873523A1 (en) | 2021-09-08 |
| US20200131241A1 (en) | 2020-04-30 |
| EA202191133A1 (ru) | 2021-07-12 |
| KR20210084528A (ko) | 2021-07-07 |
| JP2022512796A (ja) | 2022-02-07 |
| WO2020084591A1 (en) | 2020-04-30 |
| US12009079B2 (en) | 2024-06-11 |
| MA54085A (fr) | 2021-09-15 |
| EP3873523A4 (en) | 2022-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12009079B2 (en) | Type I interferon signatures and methods of use | |
| RU2527068C2 (ru) | Фармакодинамические маркеры, индуцированные интерфероном альфа | |
| JP5411129B2 (ja) | インターフェロンα誘導性薬力学的マーカー | |
| JP5727484B2 (ja) | Ｉ型インターフェロン診断法 | |
| CN101999001B (zh) | 疾病标志物及其用途 | |
| AU2009240021B2 (en) | Antiviral therapy | |
| Pulkkinen et al. | ELMOD2, a candidate gene for idiopathic pulmonary fibrosis, regulates antiviral responses | |
| JP2015504430A (ja) | Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法 | |
| TW201307845A (zh) | 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法 | |
| EP2191274A1 (en) | Method for predicting the response of a subject suffering from a viral infection of the liver to an antiviral therapy | |
| Gavriilidis et al. | Neutrophil-fibroblast crosstalk drives immunofibrosis in Crohn’s disease through IFNα pathway | |
| WO2012024236A1 (en) | LTβR BLOCKADE: METHODS FOR OPTIMIZING THERAPEUTIC RESPONSIVENESS OF PATIENTS | |
| CN101594882A (zh) | 干扰素α诱导的药代动力学标记物 | |
| JP2023549872A (ja) | ステロイド節約 | |
| JP2013021932A (ja) | 関節リウマチに対する抗ｉｌ−６受容体抗体療法の有効性の予測方法 | |
| EA048244B1 (ru) | Сигнатуры интерферона типа i и способы их применения | |
| WO2021250546A1 (en) | Micrornas as predictors of response to anti-ige therapies in chronic spontaneous urticaria | |
| Abdallah et al. | Assessment of microRNA (96) and microRNA (298) as biomarkers for diagnosis and prognosis of rheumatoid arthritis in Egyptian patients | |
| WO2009155559A1 (en) | Interferon alpha-induced pharmacodynamic markers | |
| Li | Identification and characterization of susceptibility genes and dysregulated signaling pathways in Sjögren's syndrome | |
| HK1140406A (en) | Interferon alpha-induced pharmacodynamic markers |